- Home
- Publications
- Publication Search
- Publication Details
Title
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Authors
Keywords
Mineralocorticoid receptor antagonist, Diabetes, Diabetic kidney disease
Journal
Current Diabetes Reports
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-07
DOI
10.1007/s11892-019-1123-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic Kidney Disease in Diabetes
- (2018) Philip McFarlane et al. Canadian Journal of Diabetes
- Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
- (2018) Benjamin Bonnard et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease
- (2017) Evan B. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1
- (2017) Jonatan Barrera-Chimal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- New and old agents in the management of diabetic nephropathy
- (2016) Yuliya Lytvyn et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
- (2016) Muh Geot Wong et al. DIABETES CARE
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
- (2016) LANCET
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Additive Therapy With Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy
- (2016) Mohammad G. Saklayen et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease
- (2015) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2015) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- New data do not SUPPORT triple RAAS blockade
- (2015) A. H. Jan Danser et al. Nature Reviews Nephrology
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
- (2015) Matthew R. Weir et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia
- (2014) Mikhail Kosiborod et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting Cardiac Hypertrophy
- (2014) Egbert Bisping et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
- (2014) I. H. de Boer et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
- (2013) Regina Kunz et al. ANNALS OF INTERNAL MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
- (2012) Ravi Thadhani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases
- (2012) E. Morales et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intestinal Necrosis Associated with Orally Administered Calcium Polystyrene Sulfonate without Sorbitol
- (2011) Philippe Goutorbe et al. ANNALS OF PHARMACOTHERAPY
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
- (2011) Hermann Haller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
- (2009) Bing S. Huang et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis
- (2009) G. M. Magee et al. DIABETOLOGIA
- Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease
- (2009) Ibrahim Guney et al. RENAL FAILURE
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review
- (2008) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial
- (2008) Leszek Tylicki et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
- (2008) Yoshiyuki FURUMATSU et al. HYPERTENSION RESEARCH
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
- (2008) Johannes FE Mann et al. LANCET
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now